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Non-invasive prenatal diagnosis (NIPD) of aneuploidies
by cell free fetal DNA (cff-DNA) from maternal plasma
has reached the reliability to be applied in a clinical
setting. It started with an observation that fetal DNA
fragments are present in the blood of pregnant women.
One main obstacle to be resolved had been the low con-
centration of cff-DNA among maternal DNA fragments,
in general 2 – 10 % at 10th week of pregnancy. This
problem was resolved by the technical development of
next generation sequencing applying massively parallel
sequencing of millions of DNA fragments out of a single
blood sample of 10 ml followed by bioinformatic proces-
sing of the data. Algorithms for calculations of z-scores
were validated to allow a highly accurate distinction of
pregnancies with an euploid fetus from those with a
fetus carrying certain aneuploidies. With focus on the
reliability of results it should be in mind that the cff-
DNA is derived from the cytotrophoblast, e.g. from the
placental tissue which is analyzed in CVS short term
culture. Hitherto collected clinical data show sensitivity
and specificity in agreement with a diagnostic test.
In Germany, aneuploidy testing by NIPD started in
2012. Initially, the approach allowed the detection of
trisomy 21. However, meanwhile probing for trisomy 13,
trisomy 18 and the sex chromosome constitution is feasi-
ble. At the moment, the test is indicated for women with
singleton pregnancies at an increased risk for aneuploidies.
Blood samples should not be taken before 9+0 week of
pregnancy. However, it is suggested to perform NIPD only
in conjunction with a first trimester ultrasonographic
examination for a profound judging of the fetal situation.
For the time being, testing time is reduced to 10 working
days or even less.
In Germany, by now more than 4000 tests had been
performed. In Berlin, data exceeding 250 cases had been
collected by BG Berlin Genetics. The data of NIPD will be
discussed in comparison to invasive prenatal diagnosis.
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